(Total Views: 305)
Posted On: 05/10/2019 9:12:19 PM
Post# of 154759
Bring on the NASH study, I have heard on seekingalpha and NP today, NASH clinical trial companies have market cap in the billions.
With mono, I heard 200 patients, would is great. From NP's comment, it seemed he hinted they wanted 24 weeks, and the fda said 48. But even with the 2021 timeline, BP is not going to sit around and wait. The minute they believe mono is going to be successful, they will step in. They are not concerned as much with when they get approved, but 'if'. Once the pivotal trial is approved, it is going to get very interesting, especially with good cancer data. We need to market cap to increase, this will put more and more pressure on BP. With the BLA and other milestones, I believe strongly the pressure starts happening soon. I would love it to be some other company then Gilead, but we will see.
With mono, I heard 200 patients, would is great. From NP's comment, it seemed he hinted they wanted 24 weeks, and the fda said 48. But even with the 2021 timeline, BP is not going to sit around and wait. The minute they believe mono is going to be successful, they will step in. They are not concerned as much with when they get approved, but 'if'. Once the pivotal trial is approved, it is going to get very interesting, especially with good cancer data. We need to market cap to increase, this will put more and more pressure on BP. With the BLA and other milestones, I believe strongly the pressure starts happening soon. I would love it to be some other company then Gilead, but we will see.
(0)
(0)
